Glucose-6-phosphate dehydrogenase deficiency and stroke outcomes
Authors:
- Zilin OuZOZilin Ou
- Yicong ChenYCYicong Chen
- Jianle LiJLJianle Li
- Fubing OuyangFOFubing Ouyang
- Gang LiuGLGang Liu
- Shuangquan TanSTShuangquan Tan
- Weixian HuangWHWeixian Huang
- Xiao GongXGXiao Gong
- Yusheng ZhangYZYusheng Zhang
- Zhijian LiangZLZhijian Liang
- Weisheng DengWDWeisheng Deng
- Shihui XingSXShihui Xing
- 15 September 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 95 (11) , e1471-e1478
Abstract
Objective To assess the risk of glucose-6-phosphate dehydrogenase (G6PD) on stroke prognosis, we compared outcomes between patients with stroke with and without G6PD deficiency. Methods The study recruited 1,251 patients with acute ischemic stroke. Patients were individually categorized into G6PD-deficiency and non-G6PD-deficiency groups according to G6PD activity upon admission. The primary endpoint was poor outcome at 3 months defined by a modified Rankin Scale (mRS) score ≥2 (including disability and death). Secondary outcomes included the overall mRS score at 3 months and in-hospital death and all death within 3 months. Logistic regression and Cox models, adjusted for potential confounders, were fitted to estimate the association of G6PD deficiency with the outcomes. Results Among 1,251 patients, 150 (12.0%) were G6PD-deficient. Patients with G6PD deficiency had higher proportions of large-artery atherosclerosis (odds ratio [OR] 1.53, 95% confidence interval [CI] 1.09–2.17) and stroke history (OR 1.93, 95% CI 1.26–2.90) compared to the non-G6PD-deficient group. The 2 groups differed significantly in the overall mRS score distribution (adjusted common OR 1.57, 95% CI 1.14–2.17). Patients with G6PD deficiency had higher rates of poor outcome at 3 months (adjusted OR 1.73, 95% CI 1.08–2.76; adjusted absolute risk increase 13.0%, 95% CI 2.4%–23.6%). The hazard ratio of in-hospital death for patients with G6PD-deficiency was 1.46 (95% CI 1.37–1.84). Conclusions G6PD deficiency is associated with the risk of poor outcome at 3 months after ischemic stroke and may increase the risk of in-hospital death. These findings suggest the rationality of G6PD screening in patients with stroke.Keywords
This publication has 31 references indexed in Scilit:
- Ninety-Day Outcome Rates of a Prospective Cohort of Consecutive Patients With Mild Ischemic StrokeStroke, 2012
- Quantifying the Value of Stroke Disability OutcomesStroke, 2009
- G6PD Mediterranean S188F Codon Mutation Is Common Among Saudi Sickle Cell Patients and Increases the Risk of StrokeGenetic Testing and Molecular Biomarkers, 2009
- Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemiaBlood, 2009
- Structure and function of glucose-6-phosphate dehydrogenase-deficient variants in Chinese populationHuman Genetics, 2006
- Glucose-6-Phosphate Dehydrogenase Overexpression Decreases Endothelial Cell Oxidant Stress and Increases Bioavailable Nitric OxideArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- The A376G(A+) variant of the glucose-6-phosphate dehydrogenase gene is associated with endothelial dysfunction in African AmericansJACC, 2003
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Glucose-6-phosphate: A key compound in glycogenosis I and favism leading to hyper- or hypolipidaemiaEuropean Journal of Pediatrics, 1993
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993